Loading
Cardiac Imaging and Diagnostics / Renal Transplantation Outcomes and Treatments / Transplantation: Methods and Outcomes · Journal article
Clinical Kidney Journal · July 9, 2026
A consensus or society position rather than new primary data.
This clinical guidance recommends a paradigm shift from routine protocol-driven cardiovascular screening toward individualized, symptom- and risk-factor-based assessment in kidney transplant candidates, informed by the ISCHEMIA-CKD trial finding that routine invasive strategies and prophylactic revascularization offer no clear benefit over optimal medical therapy in stable, asymptomatic patients. The authors advocate for stress echocardiography as the preferred non-invasive modality, reserving invasive coronary angiography for symptomatic patients or those with objective evidence of ischemia, and limiting revascularization to guideline-established indications.
Journal article. Patients with end-stage kidney disease evaluated for kidney transplantation.
ISCHEMIA-CKD trial demonstrated no clear benefit of routine invasive strategies or prophylactic revascularization over optimal medical therapy in stable, asymptomatic kidney transplant candidates Stress echocardiography is recommended as the preferred non-invasive modality when further cardiac evaluation is indicated Invasive coronary angiography should be reserved for patients with cardiac symptoms, reduced left ventricular ejection fraction, regional wall motion abnormalities, or moderate-to-large ischemia on stress testing
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should move away from protocol-driven screening toward personalized, symptom-guided cardiovascular assessment prior to kidney transplantation, minimizing unnecessary testing while ensuring timely transplant access. Prophylactic revascularization in asymptomatic, stable candidates is not supported and optimal medical therapy is preferred.
A clinical consensus statement synthesizing evidence from trials (notably ISCHEMIA-CKD) to recommend a shift from protocol-driven to personalized cardiovascular screening in kidney transplant candidates.
Clinicians should move away from protocol-driven screening toward personalized, symptom-guided cardiovascular assessment prior to kidney transplantation, minimizing unnecessary testing while ensuring timely transplant access. Prophylactic revascularization in asymptomatic, stable candidates is not supported and optimal medical therapy is preferred.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with end-stage kidney disease (ESKD), including those evaluated for kidney transplantation (KT). Pre-transplant CV screening has traditionally focused on detecting occult coronary artery disease and guiding revascularization to reduce perioperative risk. However, emerging evidence, most notably from the ISCHEMIA-CKD trial, has challenged this paradigm, demonstrating no clear benefit of routine invasive strategies or prophylactic revascularization in stable, asymptomatic patients over optimal medical therapy. Risk assessment in kidney transplant candidates should rely on an integrated clinical evaluation that incorporates symptoms, functional capacity, baseline electrocardiography and echocardiographic findings, and the presence of major CV risk factors. When further evaluation is indicated, stress echocardiography is generally preferred as the non-invasive modality. Invasive coronary angiography should be reserved for patients with cardiac symptoms or findings suggestive of significant ischemia, including reduced left ventricular ejection fraction, regional wall motion abnormalities (RWMAs), or moderate-to-large ischemia on stress testing. Pre-emptive revascularization should be limited to established guideline-based indications, such as left main disease, multivessel disease with reduced ejection fraction, or refractory angina despite optimal medical therapy. Non-coronary CV disorders, including heart failure, valvular disease, and pulmonary hypertension, require systematic assessment and cardiology referral. In conclusion, pre-transplant CV assessment is shifting from protocol-driven screening toward individualized, clinical suspicion-based evaluation, prioritizing optimal medical therapy, avoidance of unnecessary testing, and timely access to transplantation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.